# EDGAR Filing Document

**Accession Number:** 0001411906
**File Stem:** 0001558370-23-003597
**Filing Date:** 2023-3
**Character Count:** 6711
**Document Hash:** d96c240f99928c4351ff49b4bc3e98da
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-003597.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001558370-23-003597

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230310

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ampio Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001411906
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 260179592
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35182
- **FILM NUMBER:** 23728259

**BUSINESS ADDRESS:**
- **STREET 1:** 373 INVERNESS PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112
- **BUSINESS PHONE:** 720-437-6500

**MAIL ADDRESS:**
- **STREET 1:** 373 INVERNESS PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chay Enterprises, Inc.
- **DATE OF NAME CHANGE:** 20070910

?xml version='1.0' encoding='UTF-8'?

------

**UNITED STATESSECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): March 10, 2023**

## AMPIO PHARMACEUTICALS, INC.
**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**001-35182** | &nbsp;&nbsp;**26-0179592** |
| &nbsp;&nbsp;**(State or other jurisdiction ofincorporation)** | &nbsp;&nbsp;**(Commission File Number)** | &nbsp;&nbsp;**(IRS Employer Identification No.)** |

---

**373 Inverness Parkway, Suite 200**

**Englewood, Colorado 80112**

**(Address of Principal Executive Offices) (Zip Code)**

**Registrant's telephone number, including area code: (720) 437-6500**

**Not Applicable**

**(Former name, or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Title of each class | &nbsp;&nbsp;Trading Symbol | &nbsp;&nbsp;Name of each exchange on which registered |
| &nbsp;&nbsp;Common Stock, $0.0001 par value | &nbsp;&nbsp;AMPE | &nbsp;&nbsp;NYSE American |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure.** |

---

Ampio Pharmaceuticals, Inc. (the "Company") holds approximately $1,250,000 in a deposit account at Silicon Valley Bank. Based on the joint statement by the U.S. Treasury, Federal Reserve and the Federal Deposit Insurance Corporation ("FDIC") on March 12, 2023, the Company expects to have access to all of its deposit account funds today. The balance of the Company's cash is held in an investment account that is not a deposit account and therefore, these amounts would not be impacted by the FDIC's receivership of Silicon Valley Bank or subject to FDIC insurance limits.

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Forward-Looking Statements**

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act about Ampio that involve substantial risks and uncertainties. The forward-looking statements that are based on the Company's beliefs and assumptions and on information currently available to the Company on the date and at the time of filing of this Current Report on Form 8-K All statements other than statements of historical facts contained in this Form 8-K, including statements regarding Ampio's ability to recover its cash at Silicon Valley Bank, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "excited," "expect," "going to," "intend," "may," "opportunity," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions.

These forward-looking statements are subject to risks and uncertainties described in "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and subsequent periodic reports filed with the SEC. Except as required by law, Ampio undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this Form 8-K, even if new information becomes available in the future.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **AMPIO PHARMACEUTICALS, INC.**  | **AMPIO PHARMACEUTICALS, INC.**  |
| Date: March 13, 2023 | By: | &nbsp;&nbsp;&nbsp;/s/ Michael A. Martino |
|  |  | &nbsp;&nbsp;&nbsp;Name: Michael A. Martino |
|  |  | &nbsp;&nbsp;&nbsp;Title: Chief Executive Officer |

---